Explores the impact of lenalidomide maintenance and optimal duration on outcomes in multiple myeloma patients, suggesting reevaluation of treatment strategies.
Key Points
Lenalidomide maintenance improves patient outcomes in multiple myeloma after autologous stem cell transplant.
Evidence suggests long-term maintenance can lead to adverse effects that warrant careful consideration.
Integration of measurable residual disease assessment is essential for determining maintenance therapy strategies.
The treatment landscape is evolving, emphasizing the need for more individualized approaches in multiple myeloma.